Cite
Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
MLA
Avasarala, Jagannadha, et al. “Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?” Journal of Clinical Pharmacology, vol. 57, no. 11, Nov. 2017, pp. 1415–18. EBSCOhost, https://doi.org/10.1002/jcph.945.
APA
Avasarala, J., Jain, S., & Urrea, M. E. (2017). Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap? Journal of Clinical Pharmacology, 57(11), 1415–1418. https://doi.org/10.1002/jcph.945
Chicago
Avasarala, Jagannadha, Sandip Jain, and Mendoza, Enrique Urrea. 2017. “Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?” Journal of Clinical Pharmacology 57 (11): 1415–18. doi:10.1002/jcph.945.